Oral COTI-2 Is Effective Against Aggressive Triple Negative Human Breast Cancer
 

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced positive test results today from a series of animal experiments carried out at a prominent Canadian cancer research facility with COTI-2 as a single agent against an aggressive strain of triple negative human breast cancer (TNBC); MDA-MB-231-luc...

More...